Skip to main content
SpringerLink
Log in

Anti-CD37 targeted immunotherapy of B-Cell malignancies

  • Review
  • Published:
Biotechnology Letters Aims and scope Submit manuscript

Abstract

CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Betrian S, Ysebaert L, Heider K, Delord J, Fournié J, Quillet-Mary A (2016) Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant/relapse-initiating CLL cells: a rationale for combination treatment. Blood Cancer J 6:e496

    Article  CAS  Google Scholar 

  • Caravella J, Lugovskoy A (2010) Design of next-generation protein therapeutics. Curr Opin Chem Biol 14:520–528

    Article  CAS  Google Scholar 

  • Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343

    Article  CAS  Google Scholar 

  • Deckert J et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122:3500–3510

    Article  CAS  Google Scholar 

  • Deckert J et al (2015) IMGN529, a novel antibody-drug conjugate (ADC) targeting CD37 shows synergistic activity with rituximab in non-Hodgkin lymphoma (NHL) models. Blood 126:1548

    Google Scholar 

  • Eccles SA (2001) Monoclonal antibodies targeting cancer: magic bullets or just the trigger? Breast Cancer Res 3:86

    Article  CAS  Google Scholar 

  • Gartlan KH et al (2013) Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol 43:1208–1219

    Article  CAS  Google Scholar 

  • Gopal AK et al (2014) Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs 32:1213–1225

    Article  CAS  Google Scholar 

  • Heider K-H et al (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159–4168

    Article  CAS  Google Scholar 

  • Hellman A et al (2013) Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 122:2860

    Google Scholar 

  • Hemler ME, Mannion BA, Barditchevski F (1996) Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287:67–71

    PubMed  Google Scholar 

  • Jin L, Cambier JC (2012) SMIP-016 in action: CD37 as a death receptor. Cancer Cell 21:597–598

    Article  CAS  Google Scholar 

  • Knobeloch K-P et al (2004) A regulatory role for CD37 in T cell. J Immunol 172:2953–2961

    Article  Google Scholar 

  • Kolstad A (2016) Efficacy and safety results of Betalutin®(177 Lu-DOTA-HH1) in a phase 1/2 study of patients with non-hodgkin B-cell lymphoma (NHL). Platelets 10:100

    Google Scholar 

  • Krause G et al (2012) Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 26:546

    Article  CAS  Google Scholar 

  • Lapalombella R et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21:694–708

    Article  CAS  Google Scholar 

  • Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767

    Article  CAS  Google Scholar 

  • Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH (2018a) Ofatumumab monoclonal antibody affinity maturation through in silico modeling. Iran Biomed J 22:180

    PubMed  PubMed Central  Google Scholar 

  • Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH, Dastmalchi S (2018b) Affinity maturation and characterization of the ofatumumab monoclonal antibody. J Cell Biochem. https://doi.org/10.1002/jcb.27457

    Article  PubMed  Google Scholar 

  • Pereira DS et al (2015) AGS67E, an anti-CD37 monomethyl auristatin E antibody drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-15-0067

    Article  PubMed  PubMed Central  Google Scholar 

  • Plas DR et al (1996) Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272:1173–1176

    Article  CAS  Google Scholar 

  • Reichert JM (2012) Marketed therapeutic antibodies compendium, vol 3. Taylor & Francis, Abingdon, pp 413–415

    Google Scholar 

  • Reichert JM (2014) Antibodies to watch in 2014: mid-year update, vol 4. Taylor & Francis, Abingdon, pp 799–802

    Google Scholar 

  • Robak T, Robak P (2014) Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Therapy 14:651–661

    Article  CAS  Google Scholar 

  • Rosenwald A et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947

    Article  Google Scholar 

  • Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140:905–914

    CAS  PubMed  Google Scholar 

  • Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198

    Article  CAS  Google Scholar 

  • Stathis A et al (2014a) A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory b-cell non-hodgkin’s lymphoma (NHL). Blood 124:1760

    Google Scholar 

  • Stathis A et al (2014b) Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 35(15):8526

    Google Scholar 

  • Tarrant JM, Robb L, van Spriel AB, Wright MD (2003) Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 24:610–617

    Article  CAS  Google Scholar 

  • Tomlinson MG, Wright MD (1996) Characterisation of mouse CD37: cDNA and genomic cloning. Mol Immunol 33:867–872

    Article  CAS  Google Scholar 

  • Veenbergen S, van Spriel AB (2011) Tetraspanins in the immune response against cancer. Immunol Lett 138:129–136

    Article  CAS  Google Scholar 

  • Virtaneva KI, Angelisová P, Baumruker T, Hořejší V, Nevanlinna H, Schröder J (1993) The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes. Immunogenetics 37:461–465

    Article  CAS  Google Scholar 

  • Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32:992

    Article  CAS  Google Scholar 

  • Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1–12

    Article  CAS  Google Scholar 

  • Xu-Monette ZY et al (2016) Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2016-05-715094

    Article  PubMed  PubMed Central  Google Scholar 

  • Zapata PDO et al (2002) Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab 87:915–926

    Article  CAS  Google Scholar 

  • Zhao X et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110:2569–2577

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Shahid Rajaee Teacher Training University and Zanjan University of Medical Sciences for support to conduct this work.

Author information

Authors and Affiliations

  1. Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    Zahra Payandeh

  2. Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Effat Noori

  3. Department of Research and Production of Poultry Viral Vaccine, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran

    Bahman Khalesi

  4. Department of Clinical Biochemistry, Faculty of Medical Sciences, Dezful University of Medical Sciences, Dezful, Iran

    Maysam Mard-Soltani

  5. Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

    Jalal Abdolalizadeh

  6. Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran

    Saeed Khalili

Authors
  1. Zahra Payandeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Effat Noori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahman Khalesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maysam Mard-Soltani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jalal Abdolalizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saeed Khalili
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saeed Khalili.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Payandeh, Z., Noori, E., Khalesi, B. et al. Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnol Lett 40, 1459–1466 (2018). https://doi.org/10.1007/s10529-018-2612-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10529-018-2612-6

Keywords

Search

Navigation